Clinical trial · Observational
The Effect of Glioblastoma PSMA Expression Following Tumour VEGF Blockade From Bevacizumab
Investigating Glioblastoma PSMA Expression by Utilizing Anti-VEGF and Its Effect on PSMA PET Scan Avidity
NCT07052877CI-TRIAL-00121857GUAVArecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This trial is a single arm study for patients receiving bevacizumab for IDH-wildtype glioblastoma. Patients receiving bevacizumab (an anti-VEGF therapy) will receive PSMA scans to investigate the role of PSMA expression in glioblastoma and its relationship to VEGF expression.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioblastoma | Glioblastoma | CURATED_BROADER | 0.80 |
| Glioblastoma Multiforme (GBM) | Glioblastoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PSMA PET/CT scan | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients with glioblastoma receiving Bevacizumab as part of their standard of care
- interventionNames
- Diagnostic Test: PSMA PET/CT scan
Primary outcomes (1)
- measure
- Changes in PSMA PET metabolic tumour volume (MTV) before and after bevacizumab administration.
- timeFrame
- Prior to first administration of bevacizumab to 6 weeks after.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * \> 18 year of age * ECOG 0-2 * Able to provide informed consent for the study * Minimum of 1 month from completion of radiotherapy with clinical or radiography evidence suggesting residual tumour * Confirmed glioblastoma IDH1/2 wildtype (WHO2021) * For bevacizumab treatment as per treating physician * Able to comply with trial requirements Exclusion Criteria: * No major organ impairment that would likely lead to unacceptable toxicities- eg significant cardiac, hepatic, renal or haematologic dysfunction (based on clinician assessment) * Any contraindication to bevacizumab, MRI gadolinium contrast or 68Ga-PSMA-617 radioisotope * Any implant, foreign body, 3T MRI incompatible device or other contraindication to MRI imaging * Does not fulfill PBS requirements for bevacizumab * Women lactating, pregnant or of child baring potential who are not willing to avoid pregnancy during the study
References
Publications (0)
Data not yet available
No reference posted for this study.